IPGP: Inverse Head And Shoulders detected on 29 Sep 2026

An inverse head-and-shoulders pattern is forming with IPGP at 77.23, well below its 52-week high by 50.4% and only 11.3% above its 52-week low. The structure score of 11/15, breakout of 11/13, and volume of 10/12 indicate a moderate-quality base forming. Key support sits at 74.51 and resistance at 74.15—a tight range suggesting consolidation. Q1 2026 revenue of $265.5M drove 17% year-over-year growth, but the stock has declined 30.4% over three months. An inverse H&S with this structure suggests a reversal attempt off lows; the 61.3% win probability indicates measurable but not overwhelming conviction.

CEO Mark Gitin stated the company delivered its second consecutive quarter of double-digit year-over-year revenue growth, driven by disciplined execution of strategic initiatives and strong demand for laser solutions. More recently, the acquisition of Lumibird Medical for €300 million expands the medical laser platform into ophthalmology, increasing addressable market by $1 billion and boosting advanced solutions revenue to 26% of sales. Needham raised its price target to $120 from $110 with a Buy rating following the Lumibird Medical agreement. Q2 2026 revenue came in at $278.58M versus consensus of $279.97M, showing slight underperformance, though growth momentum persists. The strategic acquisition is positioning the company for expansion in higher-margin markets.

A successful breakout from this inverse H&S would target 81.36—a 5.3% move from current price, consistent with the measured move pattern. Volume confirmation is critical; current volume at 319,791 is running 75% of the 20-day average, suggesting buyers are still cautious. The pattern invalidates below key support of 74.51; a close below that level signals the reversal setup has failed. With a 61.3% win probability, historical precedent suggests roughly 3 out of 5 similar setups resolve higher, but this is not high-conviction. RSI of 45.84 indicates neutral positioning with room to move higher.

Citi analyst lowered the price target to $137 from $150 in August 2026, flagging concerns despite the Lumibird acquisition. Q1 2026 operating margin turned negative at -2.9% versus positive 0.8% a year prior, and net income declined 58% year-over-year to $1.6M, signaling profitability pressure despite revenue growth. High beta of 1.87 means the stock is 87% more volatile than the market—sharp downside reversals are possible. Volume is running below average (0.75 ratio), meaning the pattern lacks the conviction of institutional accumulation. Tariff headwinds are an ongoing challenge per management commentary.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.